Riparian Pharmaceuticals Inc is categorized under Commercial Biotechnical Research in Boston, MA and active since 2012.
Riparian Pharmaceuticals Inc was established in 2012, and today employs 1 to 4, earning $0 to $49.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact William Adams at the company’s single location by writing to 7 Henchman St # 405, Boston, Massachusetts MA 02113 or by phoning (914) 318-6926. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Riparian Pharmaceuticals Inc |
| Contact Person: | William Adams |
| Address: | 7 Henchman St # 405, Boston, Massachusetts 02113 |
| Phone Number: | (914) 318-6926 |
| Annual Revenue (USD): | $0 to $49.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Riparian Pharmaceuticals Inc was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $0 to $49.999 per annum.
Feel free to contact William Adams for inquiries that concern Riparian Pharmaceuticals Inc by calling the company number (914) 318-6926, as your correspondence is most welcome. Additionally, the physical location of the single location of Riparian Pharmaceuticals Inc can be found at the coordinates 42.366943,-71.053711 as well as the street address 7 Henchman St # 405 in Boston, Massachusetts 02113.
For its online presence, you may visit Riparian Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.